Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: Results from a multicenter, retrospective study in Shanghai

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 9, 2013, Pages 1579-1589

  Cai, Xun ^a   Cao, Weiguo ^a   Ding, Honghua ^a   Liu, Tianshu ^b   Zhou, Xinli ^c   Wang, Mei ^d   Zhong, Ming ^e   Zhao, Ziyi ^f   Xu, Qing ^g   Wang, Liwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f Central Hospital in jing'An District   (China)

^g TONGJI UNIVERSITY   (China)

Author keywords

Colonic neoplasms; Drug metabolism; Genetic polymorphism; Irinotecan; Uridine diphosphate glucuronosyl transferase

Indexed keywords

ADENINE; BILIRUBIN; FIRTECAN; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; THYMINE; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHINA; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DINUCLEOTIDE REPEAT; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TATA BOX; CANCER STAGING; COLORECTAL TUMOR; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; LIVER TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHINA; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84882659091     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1480-7     Document Type: Article

References (32)

1. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH et al (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26(16):2690-2698
2. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A (1996) Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 14(10):2688-2695
3. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S (2009) Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol 2:18
4. Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J (2004) Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76(6):528-535 (Pubitemid 39601543)
5. Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, Ychou M (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13(11):3269-3275 (Pubitemid 46944912)
6. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared withfluorouracil alone as first-line treatment for metastaticcolorectal cancer: A muhicentre randomised trial. Lancet 355(9209):1041-1047 (Pubitemid 30162806)
7. Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, Mahjoubi M, Méry-Mignard D, Rougier P (1999) Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 17(9):2901-2908 (Pubitemid 29415251)
8. Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, Merlin JL, Rivière A, Perrocheau G, Etienne MC, Milano G (1998) Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 4(9):2039-2045 (Pubitemid 28415645)
9. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26(13):2099-2105
10. Hirose K, Kozu C, Yamashita K, Maruo E, Kitamura M, Hasegawa J, Omoda K, Murakami T, Maeda Y (2012) Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. Oncol Lett 3(3):694-698
11. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22(8):1382-1388 (Pubitemid 41103619)
12. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ (2002a) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2(1):43-47 (Pubitemid 34982202)
13. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ (2002b) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47 (Pubitemid 34982202)
14. Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, Sawada J, Tohkin M, Hasegawa R (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C > T (P229L) found in an African-American. Drug Metab Dispos 33(3):458-465 (Pubitemid 40279948)
15. Kleibl Z, Fidlerova J, Kleiblova P, Kormunda S, Bilek M, Bouskova K, Sevcik J, Novotny J (2009) Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 56(4):303-316
16. Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS (2008) UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 112(9):1932-1940 (Pubitemid 351574068)
17. Liu Y, Xia Q, Jia Y, Guo H, Wei B, Hua Y, Yang S (2011) Significance of differential expression of thymidylate synthase in normal and primary tumor tissues from patients with colorectal cancer. J Hematol Oncol 4:33
18. Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91(4):678-682 (Pubitemid 39141623)
19. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, Lombardo M, Pilone A, Mattioli R, Leon A (2006) Uridine diphosphate glucuronosyl transferase 1 A 1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106(5):1007-1016
20. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, Sparreboom A (2004) Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44(8):854-860 (Pubitemid 38971566)
21. Reilly JJ, Workman P (1993) Normalization of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 32(6):411-418 (Pubitemid 23234656)
22. Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord JP, Fonck M, Laurand A, Poirier AL, Morel A, Chatelut E, Robert J, Gamelin E (2008) Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer 99(8):1239-1245
23. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP (1996) Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 14(11):2959-2967 (Pubitemid 26371454)
24. Schoemaker NE, Rosing H, Jansen S, Schellens JH, Beijnen JH (2003) High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma. Ther Drug Monit 25(1):120-124 (Pubitemid 36139838)
25. Shulman K, Cohen I, Barnett-Griness O, Kuten A, Gruber SB, Lejbkowicz F, Rennert G (2011) Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 117(14):3156-3162
26. Sumiyoshi H, Fujiwara Y, Ohune T, Yamaoka N, Tamura K, Yamakido M (1995) High performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J Chromatogr B Biomed Appl 670(2):309-316
27. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, Pasetto LM et al (2006) The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24(19):3061-3068 (Pubitemid 46638941)
28. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G> a mutation. Int J Cancer 101(3):253-258 (Pubitemid 34970893)
29. Wu MH, Chen P, Wu X, Liu W, Strom S, Das S, Cook EH Jr, Rosner GL, Dolan ME (2004) Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics 14(9):595-605 (Pubitemid 39281814)
30. Yang LX, Ma T, Zhang J, Ye ZB, Xiang M, Zhu ZG (2009) A study on the relationship between the adverse events of irinotecan-based chemotherapy and UGT1A1*28 gene polymorphism. J Intern Med Concepts. Pract. (Chinese) 4(4):300-304
31. Ychou M, Duffour J, Kramar A, Debrigode C, Gourgou S, Bressolle F, Pinguet F (2003) Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol 52(4):282-290 (Pubitemid 37352594)
32. Zhang A, Xing Q, Qin S, Du J, Wang L, Yu L, Li X, Xu L, Xu M, Feng G, He L (2007) Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J 7(5):333-338 (Pubitemid 47484773)